Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Hormone Receptor Positive Breast Cancer”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04298086
What this trial is testing

The Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer

Who this might be right for
Breast CancerPrimary Hormone Receptor Positive Breast Cancer
Memorial Sloan Kettering Cancer Center 43
Large-scale testing (Phase 3)Study completedNCT00256698
What this trial is testing

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

Who this might be right for
Breast Cancer
AstraZeneca 514
Post-approval studies (Phase 4)UnknownNCT03270007
What this trial is testing

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Primary Breast Cancer
Tao OUYANG 304
Testing effectiveness (Phase 2)Ended earlyNCT00206414
What this trial is testing

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Who this might be right for
BREAST CANCER
Baylor Breast Care Center 15
Large-scale testing (Phase 3)Study completedNCT00291759
What this trial is testing

ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

Who this might be right for
Breast Cancer
AstraZeneca 3,858
Large-scale testing (Phase 3)Study completedNCT03969121
What this trial is testing

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Malignant Neoplasm of Breast
Kyoto Breast Cancer Research Network 141
Testing effectiveness (Phase 2)Study completedNCT02760030
What this trial is testing

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IA Breast Cancer+6 more
Ohio State University Comprehensive Cancer Center 14
Large-scale testing (Phase 3)Study completedNCT00535418
What this trial is testing

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 35
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726
Testing effectiveness (Phase 2)Active Not RecruitingNCT04692103
What this trial is testing

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Who this might be right for
Estrogen Receptor PositivePrimary or Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 2
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Not applicableActive Not RecruitingNCT04314401
What this trial is testing

National Cancer Institute "Cancer Moonshot Biobank"

Who this might be right for
Acute Myeloid LeukemiaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+26 more
National Cancer Institute (NCI) 1,600
Not applicableEnded earlyNCT00555867
What this trial is testing

Patient's Anastrozole Compliance to Therapy Programme

Who this might be right for
Breast Cancer
AstraZeneca 4,923
Not applicableStudy completedNCT00638391
What this trial is testing

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,600
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 764
Testing effectiveness (Phase 2)WithdrawnNCT01814865
What this trial is testing

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Who this might be right for
Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
British Columbia Cancer Agency
Load More Results